Tourniquet-Test in HHT

HHT Clinical Trial

Official title:

Tourniquet-Test in HHT

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06266624
• Other study ID #: Tourniquet in HHT
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 25, 2020
• Est. completion date: July 30, 2024

Study information

• Verified date: February 2024
• Source: University Hospital, Essen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.

Description:

The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 92
• Est. completion date: July 30, 2024
• Est. primary completion date: July 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• In patients with confirmed HHT diagnosis (= 3 Curaçao criteria or positive molecular genetics)
• aged over 18 years

Exclusion Criteria:

• if inclusion criteria does not apply

Related Conditions & MeSH terms

• HHT

Intervention

Diagnostic Test:
• Tourniquet Test
Tourniquet Test was performed in patients with HHT

Locations

Country	Name	City	State
Germany	University Hospital Essen	Essen	Nordrhein Westphalen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Essen

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of positive Tourniquet Test results in HHT patients	Documentation of the number of positive Tourniquet Test results in HHT patients	three years